Woodline Partners LP Cue Biopharma, Inc. Transaction History

Woodline Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $3.1 Million - $5.09 Million	-285,133 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $3.84 Million - $5.85 Million	-382,091 Reduced 57.27%	285,133 $4.15 Million
Q2 2021 Aug 16, 2021	BUY	$10.9 - $14.53 $5.06 Million - $6.75 Million	464,418 Added 229.0%	667,224 $7.77 Million
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $3.44 Million - $4.94 Million	-307,282 Reduced 60.24%	202,806 $2.47 Million
Q4 2020 Feb 16, 2021	SELL	$11.12 - $16.4 $4.5 Million - $6.64 Million	-404,574 Reduced 44.23%	510,088 $6.38 Million
Q3 2020 Nov 16, 2020	BUY	$15.05 - $23.54 $3.84 Million - $6.01 Million	255,267 Added 38.71%	914,662 $13.8 Million
Q2 2020 Aug 14, 2020	BUY	$12.7 - $30.73 $8.37 Million - $20.3 Million	659,395 New	659,395 $16.2 Million

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $37.5M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.